aTyr Pharma, Inc. filed its Form 10-Q with the SEC on November 6, 2026, reporting financial results for the quarterly and nine-month periods ended September 30, 2026, with the company trading on NASDAQ:ATYR.

Key Highlights

  • Nine-month net loss: Net loss attributable to aTyr Pharma, Inc. was $39,361 thousand for the nine months ended September 30, 2026, compared to $60,155 thousand for the same period in 2025.
  • Third-quarter net loss: Net loss attributable to aTyr Pharma, Inc. was $18,261 thousand for the three months ended September 30, 2026, versus $25,744 thousand in Q3 2025.
  • No revenues recorded: Total revenues were $0 for both the three and nine months ended September 30, 2026, compared to $190 thousand in the same periods of 2025.
  • Cash and investments: Cash and cash equivalents were $13,140 thousand and available-for-sale investments were $35,611 thousand as of September 30, 2026, down from $10,743 thousand and $67,944 thousand, respectively, as of December 31, 2025.
  • Accumulated deficit: The accumulated deficit reached $645,525 thousand as of September 30, 2026, up from $606,164 thousand as of December 31, 2025.
  • Shares outstanding: As of November 2, 2026, there were 2,549,230 shares of common stock outstanding.
  • At-the-market offering: During Q3 2026, the company issued 59,513 shares from at-the-market offerings, raising net proceeds of $887 thousand after offering costs.

aTyr Pharma Financial Results for the Nine Months Ended September 30, 2026

According to the filing, aTyr Pharma reported a consolidated net loss of $39,359 thousand for the nine months ended September 30, 2026, compared to $60,159 thousand for the nine months ended September 30, 2025. For the third quarter alone, the consolidated net loss was $18,257 thousand, against $25,746 thousand in the year-ago quarter. Net loss per share, basic and diluted, was $7.43 for Q3 2026 and $16.04 for the nine-month period, compared to $10.60 and $26.36 for the respective prior-year periods.

The filing disclosed that total operating expenses for the nine months ended September 30, 2026 were $41,109 thousand, consisting of $24,510 thousand in research and development expenses and $16,599 thousand in general and administrative expenses. This compares to total operating expenses of $63,021 thousand for the nine months ended September 30, 2025, which included $49,328 thousand in research and development. Total other income, net, was $1,750 thousand for the nine-month period in 2026, versus $2,672 thousand in 2025.

As of September 30, 2026, the company reported total assets of $59,806 thousand and total stockholders' equity of $33,792 thousand, down from $93,003 thousand and $67,288 thousand, respectively, as of December 31, 2025. The authorized share count for common stock increased to 340,000,000 shares as of September 30, 2026, from 170,000,000 as of December 31, 2025. Stock-based compensation recorded during Q3 2026 was $2,592 thousand. The company also noted a noncontrolling interest in Pangu BioPharma Limited, which carried a balance of $(190) thousand as of September 30, 2026.

What Was Disclosed

aTyr Pharma's 10-Q for the period ended September 30, 2026 reported zero revenues, a nine-month net loss of approximately $39.4 million, total assets of $59.8 million, and an accumulated deficit of $645.5 million, with 2,549,230 shares outstanding as of November 2, 2026.